The Outcome of HyperCVAD Combined with Alemtuzumab for the Treatment of Aggressive T-Cell and NK-Cell Neoplasms.

The Outcome of HyperCVAD Combined with Alemtuzumab for the Treatment of Aggressive T-Cell and NK-Cell Neoplasms.

We report our experience in using six cycles of hyperCVAD in combination with alemtuzumab for the treatment of aggressive T-cell and NK/T-cell neoplasms. Seven females and six males with the median age of 41 (range 18–60) diagnosed with T-cell acute lymphoblastic lymphoma and peripheral T-cell...

Full description

Bibliographic Details
Main Authors: Kuan, Jew-Win, Chang, Kian-Meng, Lau, Ngee Siang, Visalachy, Purushothaman, Tan, Sen Mui, Ong, Tee Chuan, Su, Anselm-Ting
Format: Article
Language:English
Published: Elsevier Ltd. 2011
Subjects:
RZ Other systems of medicine
Online Access:http://ir.unimas.my/12281/
http://ir.unimas.my/12281/
http://ir.unimas.my/12281/7/A%20randomized%20double%20blind%20control%20trial%20comparing%20filgrastim%20%28abstract%29.pdf

Internet

http://ir.unimas.my/12281/
http://ir.unimas.my/12281/
http://ir.unimas.my/12281/7/A%20randomized%20double%20blind%20control%20trial%20comparing%20filgrastim%20%28abstract%29.pdf

Similar Items